Primecap Management Co. CA trimmed its position in Nektar Therapeutics (NASDAQ:NKTR – Free Report) by 13.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,020,453 shares of the biopharmaceutical company’s stock after selling 946,194 shares during the quarter. Primecap Management Co. CA owned about 3.27% of Nektar Therapeutics worth $7,465,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently modified their holdings of NKTR. GSA Capital Partners LLP increased its holdings in Nektar Therapeutics by 185.5% in the 4th quarter. GSA Capital Partners LLP now owns 5,255,790 shares of the biopharmaceutical company’s stock worth $2,970,000 after buying an additional 3,414,712 shares during the period. State Board of Administration of Florida Retirement System acquired a new stake in shares of Nektar Therapeutics in the first quarter worth $63,000. Values First Advisors Inc. purchased a new position in shares of Nektar Therapeutics during the second quarter worth $56,000. SG Americas Securities LLC raised its holdings in shares of Nektar Therapeutics by 63.0% during the second quarter. SG Americas Securities LLC now owns 73,352 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 28,338 shares during the last quarter. Finally, Candriam S.C.A. acquired a new position in Nektar Therapeutics during the second quarter valued at $99,000. Institutional investors and hedge funds own 75.88% of the company’s stock.
Nektar Therapeutics Trading Down 3.1 %
Nektar Therapeutics stock opened at $1.26 on Thursday. The firm has a market cap of $231.87 million, a PE ratio of -1.40 and a beta of 0.60. The stock’s 50 day simple moving average is $1.28 and its two-hundred day simple moving average is $1.28. Nektar Therapeutics has a 12 month low of $0.41 and a 12 month high of $1.93.
Analysts Set New Price Targets
Separately, Rodman & Renshaw began coverage on Nektar Therapeutics in a research report on Friday, June 28th. They set a “buy” rating and a $2.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $1.50.
View Our Latest Stock Analysis on Nektar Therapeutics
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Read More
- Five stocks we like better than Nektar Therapeutics
- When to Sell a Stock for Profit or Loss
- How Much Can You Make in Stocks in One Month?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- This Is the Top Large-Cap Stock Insiders Are Buying
- How to Invest in Small Cap Stocks
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR – Free Report).
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.